Related Experiment Videos
Dopaminergic agonists for hepatic encephalopathy
B Als-Nielsen1, L L Gluud, C Gluud
1Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Department 7102, H:S Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Bodil.a@ctu.rh.dk
The Cochrane Database of Systematic Reviews
|October 21, 2004
Summary
Dopaminergic agonists showed no significant benefit for hepatic encephalopathy patients in this review. Limited trials and low quality mean evidence is insufficient to exclude a potential effect, but current use is not recommended.
Area of Science:
- Hepatology
- Neuroscience
- Clinical Pharmacology
Background:
- Hepatic encephalopathy (HE) may involve impaired dopaminergic neurotransmission.
- Dopaminergic agonists are hypothesized to benefit HE patients.
Purpose of the Study:
- To evaluate the efficacy and safety of dopaminergic agonists for treating hepatic encephalopathy.
- To assess the beneficial and harmful effects of dopaminergic agonists in HE patients.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) comparing dopaminergic agonists to placebo or no intervention.
- Searches included major databases (MEDLINE, EMBASE, Cochrane) and manual searches.
- Data extraction and analysis were performed independently, using random-effects models for binary outcomes.
Main Results:
- Five trials (low methodological quality) were included.
- Dopaminergic agonists did not significantly improve outcomes like "no improvement" or mortality compared to placebo.
- A trend towards adverse events was observed, though not statistically significant due to small sample sizes.
Conclusions:
- Current evidence does not support the use of dopaminergic agonists for hepatic encephalopathy.
- The review is limited by the small number and low quality of included trials.
- Further high-quality randomized clinical trials are needed to definitively assess the role of dopaminergic agonists in HE.